| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.01.23 | Context Therapeutics - Elacestrant approval shot in the arm for ELONA trial | 467 | Edison Investment Research | On 27 January, the US FDA approved Stemline Therapeutics' (wholly owned US subsidiary of the Menarini group) elacestrant (Orserdu) as second-line treatment for ER+/HER2-, ESR1-mutated advanced or metastatic... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 328 |
| EVOTEC | 291 |
| TUI | 209 |
| NVIDIA | 177 |
| DEUTSCHE BANK | 170 |
| BAYER | 155 |
| PLUG POWER | 143 |
| NEL | 133 |
| RHEINMETALL | 129 |
| SIEMENS ENERGY | 110 |
| BARRICK GOLD | 109 |
| COMMERZBANK | 107 |
| TESLA | 102 |
| BASF | 101 |
| VOLKSWAGEN | 93 |
| RWE | 89 |
| BYD | 87 |
| DEUTSCHE LUFTHANSA | 85 |
| ALLIANZ | 82 |
| RENK GROUP | 79 |
| MERCEDES-BENZ | 78 |
| DEUTSCHE TELEKOM | 75 |
| HEIDELBERGER DRUCK | 75 |
| ALIBABA | 71 |
| E.ON | 69 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
